ArticleInternational journal of molecular medicine2020
Construction and expression of recombinant uricase‑expressing genetically engineered bacteria and its application in rat model of hyperuricemia.
Article in International journal of molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Reprogramming probiotic for uric acid modular degradation and hyperuricemia treatment by synthetic biology regulation.Microbial cell factories · 2026Article
- Gut microbiota: a potential therapeutic target for hyperuricemia and gout.Bioscience of microbiota, food and health · 2026Review
- Dual mechanisms of a purified root extract ofFrontiers in pharmacology · 2026Article
- The influence of gut microbiota on the gut-brain-kidney axis and its implications for chronic kidney disease.Frontiers in microbiology · 2025Review
- Isolation and identification of uric acid-dependentmSphere · 2024Article
- Biodegradation of Uric Acid byMicroorganisms · 2023Article
- Oral Delivery of Nanoparticles Carrying Ancestral Uricase Enzyme Protects against Hyperuricemia in Knockout Mice.Biomacromolecules · 2023Article
- Rational design of a genome-based insulated system inBioengineering & translational medicine · 2023Article
- Phylogenetic Articulation of Uric Acid Evolution in Mammals and How It Informs a Therapeutic Uricase.Molecular biology and evolution · 2022Article
- Modulation of Urate Transport by Drugs.Pharmaceutics · 2021Review
- Aboriginal Bacterial Flora in the Uricase-Deficient Rat Gut is Not the Main Factor Affecting Serum Uric Acid.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Empowering probiotics with high xanthine transport for effective hyperuricemia management.Gut microbesArticle
- EngineeredGut microbesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At present, the treatment of hyperuricemia is designed primarily to decrease the production of uric acid using xanthine oxidase inhibitors; however, the therapeutic effect is not satisfactory. Therefore, the key to the successful treatment of hyperuricemia is to increase the excretion of uric acid. The aim of present study was to construct uricase‑expressing genetically engineered bacteria and analyze the effects of these engineered bacteria on the lowering of uric acid levels in a rat model of hyperuricemia. The uricase expression vector was constructed by gene recombination technology and transfected into Escherichia coli. The expression and activity of uricase were analyzed by SDS‑PAGE analysis and Bradford assay. The water consumption, food intake, body weight, eosinophil count and intestinal histology, in addition to the levels of serum uric acid (SUA) and allantoin in the feces of the rats, were assessed. The intestinal contents of the rats were analyzed by 16S rDNA sequencing technology. The results demonstrated that uricase‑expressing genetically engineered bacteria secreted active uricase. All rats exhibited a natural growth trend during the entire experiment, and the SUA of hyperuricemic rats treated with uricase‑expressing engineered bacteria was significantly decreased. In conclusion, these results indicate that uricase secreted by recombinant uricase‑expressing genetically engineered bacteria served an important role in decreasing SUA levels in a rat model of hyperuricemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.